Developer,Category,Stage,Anticipated Next Steps,Funder,Date Last Updated
Scancell/ University of Nottingham/ Nottingham Trent University,DNA-based,Pre-clinical,Phase I COVIDITY clinical trial expected to start as soon as possible during 2021,Unknown,1/19/2021
Entos Pharmaceuticals/ Cytiva,DNA-based,Pre-clinical,Phase I/II expected to begin March 2021,Canadian Institutes of Health Research (CIHR)/ Research Nova Scotia (RNS)/ Institute for Ageing (IA)/ National Research Council of Canada Industrial Research Assistance Program (NRC IRAP),2/27/2021
BioNet Asia/ Technovalia/ Vax4COVID/ The University of Sydney/ The University of Western Australia/ Telethon Kids Institute/ PharmaJet,DNA-based,Pre-clinical,Phase I expected to begin February 2021,Australian Government Medical Research Future Fund (MRFF),2/16/2021
Inovio Pharmaceuticals/ Beijing Advaccine Biotechnology/ VGXI Inc./ Richter-Helm BioLogics/ Ology Bioservices/ International Vaccine Institute/ Seoul National University Hospital/ Thermo Fisher Scientific/ Kaneka Eurogentec,DNA-based,Phase II/III,"Phase I data published December 2020; Phase II dosed December 2020, as part of its Phase II/III clinical trial (INNOVATE); FDA partial clinical hold for planned Phase II/III trial reported on 9/28/2020; Phase I/IIa trial began July 2020; Animal study results released July 2020; Joined US Operation Warp Speed in June 2020; Phase I began April 2020, interim data of ongoing study released June 2020",Coalition for Epidemic Preparedness (CEPI) / Gates Foundation / US Department of Defense,1/31/2021
University of Cambridge/ DIOSynVax/ PharmaJet,DNA-based,Pre-clinical,Phase I expected to begin late fall 2020 or early 2021,Innovate UK,10/28/2020
Mediphage Bioceuticals/ University of Waterloo/ Lambton College,DNA-based,Pre-clinical,Unknown,Unknown,9/23/2020
Symvivo,DNA-based,Phase I,Phase I dosed November 2020,National Research Council of Canada Industrial Research Assistance Program (NRC IRAP),11/2/2020
Takis/ Applied DNA Sciences/ Evvivax/ Rottapharm Biotech,DNA-based,Pre-clinical,"Phase I/II expected to begin March 2021, announced the authorization of the clinical trial by the Italian Medicines Agency (AIFA) on 2/3/2021; Pre-clinical results released in May and July 2020",Unknown,3/16/2021
Immunomic Therapeutics/ EpiVax/ PharmaJet,DNA-based,Pre-clinical,Unknown,Unknown,Prior to 4/20/2020
Zydus Cadila Healthcare Limited ,DNA-based,Phase III,"Phase III dosed January 2021; Pre-clinical results released January 2021; DCGI approved start of Phase III trial in January 2021; Phase I/II study: Phase I began July 2020 and Phase II began August 2020, initial results expected September 2020",Unknown,1/31/2021
OPENCORONA Project: Karolinska Institute/ Justus Liebig University Giessen/ Public Health Agency of Sweden (FoHM)/ IGEA/ Cobra Biologics/ Adlego Biomedical/ Region Stockholm,DNA-based,Pre-clinical,Phase I expected to begin in 2020,European Commission (Horizon 2020 Program),9/23/2020
Osaka University/ AnGes/ Takara Bio/ Cytiva/ Brickell Biotech,DNA-based,Phase II/III,"Phase II/III trial began December 2020; Pre-clinical study results released October 2020; Phase I/II trials began end of June (AG0301) and August (AG0302) 2020, results expected during Q1 2021",Unknown,1/31/2021
"Genexine Consortium (GenNBio, International Vaccine Institute, Korea Advanced Institute of Science and Technology (KAIST), Pohang University of Science and Technology (POSTECH)/ Binex/ PT Kalbe Pharma",DNA-based,Phase I/II,Updated development plan to GX-19N formula and will reconduct Phase I/IIa study as of December 2020. Phase I of Phase I/IIa study began end of June 2020; Animal study results announced August 2020,Unknown,1/31/2021
Chula Vaccine Research Center,DNA-based,Pre-clinical,Unknown,Unknown,9/23/2020
"National
  Research Centre, Egypt",DNA-based,Pre-clinical,Unknown,Unknown,6/30/2020
Ege University Drug Development and Pharmacokinetic Research Application Center (ARGEFAR)/ Scientific and Technological Research Council of Turkey (TUBITAK),DNA-based,Pre-clinical,Unknown,Unknown,9/23/2020
"Statens Serum Institute, Denmark",DNA-based,Pre-clinical,Phase I is expected to start in late 2020 or early 2021,Folketing's Finance Committee,11/16/2020
"Globe Biotech Limited, Bangladesh",DNA-based,Pre-clinical,Unknown,Unknown,11/9/2020
"National Institute of Chemistry, Slovenia",DNA-based,Pre-clinical,Unknown,Unknown,11/9/2020
OncoSec Medical Incorporated / Providence Cancer Institute ,DNA-based,Phase I,Phase I dosed January 2021,Unknown,2/2/2021
"GeneOne
  Life Science",DNA-based,Phase I/II,Phase I/IIa began December 2020,Unknown,1/18/2021
"Valneva/ Dynavax/ National Institute for Health Research, United Kingdom",Inactivated virus,Phase I/II,Phase I/II began December 2020,Unknown,1/31/2021
Beijing Institute of Biological Products/ Sinopharm ,Inactivated virus,Phase III,"Hungary granted ""emergency use"" approval on 1/29/2021; Pakistan granted ""emergency use authorization"" on 1/18/2021; China ""granted conditional market approval"" on 12/31/2020; Midterm clinical results released on 12/30/2020; Bahrain National Health Regulatory Authority (NHRA) ""approved"" on 12/13/2020; UAE Ministry of Health and Prevention (MOHAP) announced ""official registration"" on 12/9/2020, following review of Phase III interim analysis; Phase I/II results published October 2020; Phase III trial began July 2020; Received early approval for ""emergency use"" in China (Aug 2020) and the UAE (Sep 2020)",Unknown,1/31/2021
Wuhan Institute of Biological Products/ Sinopharm,Inactivated virus,Phase III,"Applied for regulatory approval in China as of February 2021; Phase III trial began July 2020; Phase I/II early trial results released June 2020, Phase I/II interim analysis published August 2020; Received early approval for ""emergency use"" in China (Aug 2020) and the UAE (Sep 2020)",Unknown,2/22/2021
"Research Institute for Biological Safety Problems, Republic of Kazakhstan",Inactivated virus,Phase III,"Kazakhstan granted ""temporary registration for nine months"" as of 1/13/2021; Phase III began December 2020; Phase I/II began September 2020",Unknown,1/18/2021
"Institute of Medical Biology, Chinese Academy of Medical Sciences",Inactivated virus,Phase III,"Phase III dosed (Malaysia) late January 2021; Phase II began June 2020; Phase I began May 2020, results released October 2020",Unknown,1/31/2021
Sinovac/ Dynavax,Inactivated virus,Pre-clinical,Unknown,Unknown,4/28/2020
Osaka University / BIKEN / NIBIOHN,Inactivated virus,Pre-clinical,Unknown,Unknown,Prior to 4/20/2020
Sinovac/ Instituto Butantan/ Bio Farma,Inactivated virus,Phase III,"China's NMPA granted ""conditional marketing authorization"" on 2/8/2021; Phase III results (Brazil, Turkey, Indonesia, Chile) announced on 2/5/2021; Phase I/II safety, tolerability, and immunogenicity data in adults aged 60 years and older published on 2/3/2021; Sinovac filed for ""conditional market authorization"" with China’s National Medical Products Administration (NMPA) on 2/3/2021; Chile granted ""emergency use"" approval on 1/20/2021; Brazil granted ""temporary authorization for emergency use"" on 1/17/2021; Turkey granted ""emergency use authorization"" on 1/31/2021; Indonesia granted ""emergency use approval"" on 01/11/2021; Phase III efficacy results (Brazil) released early January 2021; Phase I/II complete analysis results published 11/17/2020; Phase III trial resumed in Brazil on 11/11/2020, Phase III trial suspended in Brazil on 11/09/2020; Received approval for Phase I/II trial in adolescents and children in September 2020; Phase III trial began end of July 2020; Phase II began June 2020, mid-phase II results released August 2020; Preliminary results from Phase I/II trials released June and September 2020 (aged 60+) 2020; Received early approval for ""emergency use"" in China (Aug 2020)",Unknown,2/11/2021
"Shenzhen Kangtai Biological Products Co.,Ltd./ Beijing Minhai Biotechnology Co., Ltd.",Inactivated virus,Phase II,Phase I/II study began October 2020,Unknown,1/31/2021
"National Research Centre, Egypt",Inactivated virus,Pre-clinical,Unknown,Unknown,6/30/2020
KM Biologics,Inactivated virus,Pre-clinical,Unknown,Unknown,7/9/2020
Selcuk University,Inactivated virus,Pre-clinical,Unknown,Unknown,9/23/2020
Bharat Biotech/ Indian Council of Medical Research/ National Institute of Virology/ Ocugen/ Precisa Medicamentos,Inactivated virus,Phase III,"Phase III interim analysis results announced 3/3/2021; Neutralization of UK-variant with vaccine-elicited sera announced January 2021; India granted ""permission for emergency use"" on 01/03/2021; Phase I and II safety and immunogenicity data released December 2020 and published January 2021; Phase III began November 2020; Phase I/II study: Phase I began July 2020 and Phase II began September 2020, initial results expected September 2020; Animal study results released September 2020",Unknown,3/4/2021
Erciyes University,Inactivated virus,Phase II,"Phase II dosed February 2021; Phase I began November 2020, completed on December 14, 2020",Unknown,2/12/2021
Kocak Farma Ilac ve Kimya San. A.S.,Inactivated virus,Pre-clinical,Unknown,Unknown,11/9/2020
Institute of Vaccines and Medical Biologicals (IVAC; Vietnam) / Dynavax / PATH,Inactivated virus,Pre-clinical,Unknown,Unknown,11/9/2020
"Government
  Pharmaceutical Organization (GPO; Thailand) / Dynavax / PATH",Inactivated virus,Pre-clinical,Unknown,Unknown,11/9/2020
"Institute
  Butantan (Brazil) / Dynavax / PATH",Inactivated virus,Pre-clinical,Unknown,Unknown,11/9/2020
Shifa Pharmed Industrial Co,Inactivated virus,Phase I,Phase I began end of December 2020,Unknown,3/4/2021
Indian Immunologicals Ltd/ Griffith University,Live attenuated virus,Pre-clinical,Unknown,Unknown,4/28/2020
Codagenix / Serum Institute of India,Live attenuated virus,Phase I,"Phase I trial dosed January 2021, initial data expected by mid-2021; Phase I recruitment began December 2020",Unknown,1/31/2021
Meissa Vaccines ,Live attenuated virus,Pre-clinical,Phase I enrollment expected to begin in the U.S. by the end of March 2021,Unknown,3/16/2021
Mehmet Ali Aydinlar University/ Acıbadem Labmed Health Services A.S.,Live attenuated virus,Pre-clinical,Unknown,Unknown,7/9/2020
Greffex,Non-replicating viral vector,Pre-clinical,Unknown,Unknown,Prior to 4/20/2020
ReiThera/ Leukocare/ Univercells/ National Institute of Infectious diseases Lazzaro Spallanzani ,Non-replicating viral vector,Phase I,"Phase II/III is expected to begin March 2021; Phase I advanced to second set of three cohorts (aged 65-85 years) in November 2020; Phase I began August 2020, completed the first set of three cohorts (aged 18-55 years), preliminary results announced November 2020; Phase II/III trial expected to begin in the coming months",Unknown,3/16/2021
Stabilitech Biopharma Ltd,Non-replicating viral vector,Pre-clinical,Unknown,Unknown,5/4/2020
Bharat Biotech/ Thomas Jefferson University,Non-replicating viral vector,Pre-clinical,Pre-clinical data published October 2020,Unknown,2/27/2021
GeoVax / BravoVax/ NIAID/ NIH/ University of Texas Medical Branch ,Non-replicating viral vector,Pre-clinical,"Awarded a Small Business Innovative Research (SBIR) grant in January 2021 to support the ongoing design, construction, and preclinical testing in preparation for human clinical trials",National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH),1/25/2021
CanSino Biologics/ Beijing Institute of Biotechnology/ Petrovax ,Non-replicating viral vector,Phase III,"Filed ""conditional marketing authorization"" with China's National Medical Products Administration (NMPA) on 2/24/2021; Phase III dosed September 2020; Phase II began April 2020, initial results released May 2020, mid-phase results released July 2020; China’s Central Military Commission ""approved the use of the vaccine by the military"" in June 2020",Unknown,2/25/2021
Altimmune / University of Alabama at Birmingham,Non-replicating viral vector,Pre-clinical,Phase I commenced enrollment on 2/25/2021; Phase I expected to begin February 2021; FDA issued clinical hold for planned Phase I trial on 12/22/2020;Pre-clinical data released October 2020,Unknown,2/27/2021
German Center for Infection Research (DZIF)/ IDT Biologika GmbH/ Universitätsklinikum Hamburg-Eppendorf/ Philipps University Marburg Medical Center/ Ludwig-Maximilians University of Munich,Non-replicating viral vector,Phase I,"Clinical testing suspended January 2021, Phase II postponed until further notice; Phase I dosed October 2020",Unknown,1/14/2021
ImmunityBio/ NantKwest,Non-replicating viral vector,Phase I,"Phase I dosed in South Africa and the U.S. in March 2021; FDA authorized the expansion of the active Phase I trial and a second trial to test a novel combination of T-cell-based hAd5 subcutaneous prime vaccine with a room-temperature oral or sublingual boost; Phase I interim data announced November 2020; Pre-clinical data released December, November, and July 2020; Phase I trial dosed in the U.S. in October 2020; Selected for US Operation Warp Speed in May 2020",Unknown,3/14/2021
Valo Therapeutics Ltd,Non-replicating viral vector,Pre-clinical,Unknown,Unknown,5/4/2020
Shenzhen Geno-Immune Medical Institute,Non-replicating viral vector,Phase I/II,Phase I/II reportedly began March 2020,Unknown,1/31/2021
"Centro Nacional Biotecnologia (CNB-CSIC), Spain",Non-replicating viral vector,Pre-clinical,Unknown,Unknown,Prior to 4/20/2020
Janssen Pharmaceutical Companies/ Beth Israel Deaconess Medical Center/ Emergent BioSolutions/ Catalent/ Biological E/ Grand River Aseptic Manufacturing (GRAM)/ Sanofi/ Merck,Non-replicating viral vector,Authorized,"Granted Conditional Marketing Authorization by European Commission on 3/11/2021; Granted ""Interim Order (IO) authorization"" for emergency use by Health Canada on 3/5/2021; U.S. CDC's Advisory Committee on Immunization Practices (ACIP) has recommended the first single-shot COVID-19 vaccine for individuals 18 years of age and older on 2/28/2021; U.S. FDA issued ""emergency use authorization"" on 2/27/2021; Submitted ""emergency use listing"" to the World Health Organization (WHO) on 2/19/2021; Submitted ""conditional marketing authorisation application"" to the European Medicines Agency (EMA) on 2/16/2021; Janssen submitted application for ""emergency use authorization"" to the U.S. FDA on 2/4/2021; Phase III interim analysis results announced 1/29/2021; Phase I/IIa interim results published 1/13/2021; Phase III trial to study the safety and efficacy of a two-dose regimen began 11/15/2020 (ENSEMBLE 2); Phase III trial (ENSEMBLE) resumed recruitment on 10/23/2020, fully enrolled with ~45,000 participants as of 12/17/2020, interim data expected by the end of January 2021; Janssen Pharmaceutical Companies of Johnson & Johnson voluntarily paused dosing to allow independent review of safety data on 10/12/2020; Phase III trial (ENSEMBLE) began and study protocol released September 2020; Phase I/IIa began end of July 2020, interim results released September 2020; Animal study results published July and September 2020; Selected for US Operation Warp Speed in February 2020 and awarded funding in August 2020",Biomedical Advanced Research and Development Authority (BARDA),3/14/2021
Vaxart/ Emergent BioSolutions,Non-replicating viral vector,Phase I,"Phase II expected to begin Q2 2021; Phase I preliminary data announced 2/3/2021; Phase I dosed October 2020; FDA clearance for Phase I trial received September 2020, recruiment expected to begin September 2020; Pre-clinical results released September 2020; Data from ongoing animal challenge study released October and November 2020",Unknown,3/9/2021
University of Georgia/ University of Iowa,Non-replicating viral vector,Pre-clinical,Unknown,Unknown,4/28/2020
"University of Oxford, Oxford Biomedica, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., Merck KGaA, the Serum Institute, Vaccitech, Catalent, CSL, and AstraZeneca/IQVIA",Non-replicating viral vector,Authorized,"World Health Organization (WHO) granted Emergency Use Listing (EUL) on 2/15/2021; Phase II study in children between the ages of 6 and 17 years expected to begin in February 2021; Phase III (U.K., Brazil) and Phase I/II (U.K., South Africa) analyses data released on 2/3/2021; European Union (EU) granted ""conditional marketing authorisation"" on 1/29/2021; Brazil granted ""temporary authorization for emergency use"" on 1/17/2021; Pakistan granted ""emergency use authorization"" on 1/15/2021; India granted ""emergency use authorisation"" as well as Dominican Republic, El Salvador, Mexico and Morocco as of 1/6/2021; Argentina authorized under ""emergency registration"" on 12/30/2020;  U.K. ""authorised for emergency supply"" on 12/30/2020; Phase I/II data (w/ booster dose) published on 12/17/2020; Phase III trials interim analysis results published 12/8/2020; Phase II/III (COV002) and Phase III (COV003) trial pooled interim analysis results released on 11/23/2020; Phase II/III trial interim results released Nov 2020; Study protocol for late-stage clinical trials released September 2020; AstraZeneca clinical trials resumed globally (in the UK on 9/14/2020, Brazil and South Africa on 9/15/2020, Japan on 10/2/2020, and the US on 10/23/2020); AstraZeneca voluntarily paused vaccination to allow independent review of safety data on 9/8/2020; Phase III trial began Jun 2020 and expanded into US in Aug 2020; Phase II/III began May 2020; Phase I/II trial interim results released Jul 2020; Selected for US Operation Warp Speed in May 2020","Coalition for Epidemic Preparedness Innovations (CEPI)/ UK Government/ Biomedical Advanced Research and Development Authority (BARDA)/ Gavi, the Vaccine Alliance",2/16/2021
"IDIBAPS- Hospital Clinic, Spain",Non-replicating viral vector,Pre-clinical,Unknown,Unknown,6/1/2020
"National Center for Genetic Engineering and Biotechnology (BIOTEC)/ GPO, Thailand",Non-replicating viral vector,Pre-clinical,Unknown,Unknown,6/1/2020
"Massachusetts Eye and Ear/ AveXis, a Novartis Company/  Viralgen/ Aldevron/ Catalent/ Penn Medicine",Non-replicating viral vector,Pre-clinical,Pre-clinical results released January 2021; Phase I to begin second half of 2020,Gates Foundation,1/29/2021
Gamaleya Research Institute,Non-replicating viral vector,Phase III,"Announced the start of the rolling review process with the European Medicines Agency (EMA) on 3/4/2021; Authorized for ""emergency use"" in 39 countries as of March 2021; Phase III interim analysis results published on 2/2/2021; ""Registered"" in Belarus in December 2020; Phase III final control point data analysis results released December 2020, interim data analysis results released November 2020; Phase III (post-registration) trial began September 2020; Phase I/2 began June 2020, results published September 2020; Russian Ministry of Health ""registered"" vaccine in August 2020, Mass production expected to begin September 2020",Russian Direct Investment Fund (RDIF),3/9/2021
"National
  Research Centre, Egypt",Non-replicating viral vector,Pre-clinical,Unknown,Unknown,6/30/2020
ID Pharma,Non-replicating viral vector,Pre-clinical,Unknown,Unknown,7/9/2020
Ankara University,Non-replicating viral vector,Pre-clinical,Unknown,Unknown,7/9/2020
Erciyes University,Non-replicating viral vector,Pre-clinical,Unknown,Unknown,8/3/2020
"Institut
  Pasteur/ TheraVectys",Non-replicating viral vector,Pre-clinical,Animal study results released July 2020,Unknown,9/2/2020
"CanSino Biologics/ Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",Non-replicating viral vector,Pre-clinical,Phase I recruitment began end of September 2020,Unknown,11/2/2020
University of Helsinki/ University of Eastern Finland,Non-replicating viral vector,Pre-clinical,Unknown,Unknown,11/9/2020
"Globe Biotech Limited, Bangladesh",Non-replicating viral vector,Pre-clinical,Unknown,Unknown,11/9/2020
"City of
  Hope Medical Center",Non-replicating viral vector,Phase I,Phase I dosed December 2020,Unknown,2/27/2021
Bharat Biotech International Limited,Non-replicating viral vector,Pre-clinical,Phase I expected to begin March 2021,Unknown,2/27/2021
Heat Biologics (Zolovax)/ University of Miami/ Waisman Biomanufacturing,Protein subunit,Pre-clinical,Animal data released August 2020,Unknown,8/13/2020
Sanofi Pasteur/ GSK,Protein subunit,Phase II,Phase II with refined antigen formulation began February 2021; Phase I/II interim safety and immunogenicity results released January 2021; Phase IIb expected to begin February 2021; Phase I/II interim results announced December 2020; Phase I/II began September 2020; Selected for US Operation Warp Speed in April 2020 and awarded funding in July 2020,Biomedical Advanced Research and Development Authority (BARDA)/ US Department of Health and Human Services (HHS)/ US Department of Defense (DoD),3/9/2021
iBio / CC-Pharming,Protein subunit,Pre-clinical,Unknown,Unknown,Prior to 4/20/2020
ImmunoPrecise/ LiteVax BV,Protein subunit,Pre-clinical,Unknown,TRANSVAC2,7/15/2020
Novavax/Emergent Biosolutions/ Praha Vaccines/ Biofabri/ Fujifilm Diosynth Biotechnologies/ FDB/ Serum Institute of India/ SK bioscience/ Takeda Pharmaceutical Company Limited/ AGC Biologics/ PolyPeptide Group/ Endo,Protein subunit,Phase III,"Phase III (UK) and Phase IIb ( South Africa) final efficacy results released 3/11/2021; Phase I/II trial dosed in Japan on 2/26/2021; Phase III trial (PREVENT-19) completed enrollment in the US and Mexico on 2/22/2021; Announced the start of the rolling review process with several regulatory agencies worldwide on 2/4/2021, including the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), U.K. Medicines and Healthcare products Regulatory Agency (MHRA), and Health Canada; Phase III (UK) and Phase IIb ( South Africa) interim results released 1/28/2021; Phase III trial (PREVENT-19) initiated in the US and Mexico in December 2020, trial protocol released on website; FDA granted Fast Track Designation on 11/9/2020; Phase III dosed in the UK in October 2020, trial protocol released on website, interim data expected to be released in Q1 2021; Phase IIb trial began Aug 2020; Selected for US Operation Warp Speed July 2020; Phase I/II began end of May 2020, interim data expected to be released on 10/30/2020; Animal study & preliminary Phase I results released Aug 2020, Phase I results published Sept 2020",Coalition for Epidemic Preparedness (CEPI)/ US Department of Defense/ Gates Foundation,3/14/2021
Vaxine Pty Ltd/ Flinders University/ Oracle/ Medytox/ Sypharma/ Oxford Expression Technologies,Protein subunit,Phase I,Phase I trial began July 2020,Innovate UK/ Australian Government,10/1/2020
"Shionogi & Co., Ltd./ National Institute of Infectious Disease, Japan",Protein subunit,Phase I/II,Phase I/II began December 2020,Japan Agency for Medical Research and Development ,1/5/2021
ExpreS2ion,Protein subunit,Pre-clinical,Unknown,Unknown,Prior to 4/20/2020
"LakePharma, Inc.",Protein subunit,Pre-clinical,Unknown,Unknown,5/4/2020
Axon Neuroscience SE,Protein subunit,Pre-clinical,Pre-clinical results released September 2020,Unknown,11/16/2020
Medigen Vaccine Biologics Corp/ NIAID/ Dynavax,Protein subunit,Phase II,Phase II dosed January 2021; Phase I dosed in early October 2020; Received conditional approval for clinical testing on Aug 31 and was given full approval on Sept 30; Pre-clinical data released August 2020 and published November 2020,Unknown,1/28/2021
Baylor College of Medicine,Protein subunit,Pre-clinical,Unknown,Unknown,Prior to 4/20/2020
Innovax / Xiamen University / GSK,Protein subunit,Pre-clinical,Unknown,Unknown,Prior to 4/20/2020
Quadram Institute Biosciences,Protein subunit,Pre-clinical,Unknown,Unknown,5/12/2020
"Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology, Chinese Academy of Sciences",Protein subunit,Phase III,Phase III began December 2020; Phase I and II safety and immunogenicity data released December 2020; Phase II began July 2020; Received approval to launch clinical trials in China in June 2020,Unknown,12/30/2020
Yisheng Biopharma,Protein subunit,Pre-clinical,Unknown,Unknown,5/4/2020
"University of California, San Diego",Protein subunit,Pre-clinical,Unknown,National Science Foundation (Rapid Response Research [RAPID] grant),4/28/2020
Intravacc/Epivax,Protein subunit,Pre-clinical,Unknown,Unknown,5/19/2020
AJ Vaccines,Protein subunit,Pre-clinical,Unknown,Unknown,Prior to 4/20/2020
"VIDO-InterVac, University of Saskatchewan",Protein subunit,Phase I/II,Phase I/II dosed February 2021; Animal testing results expected in April 2020,The Government of Saskatchewan and the Canadian Federal Government,2/27/2021
MIGAL Galilee Research Institute,Protein subunit,Pre-clinical,Unknown,Unknown,Prior to 4/20/2020
Biological E Ltd/ Dynavax/ Baylor College of Medicine,Protein subunit,Phase I/II,"CEPI partnership announced December 2020; Phase I/II began November 2020, interim data expected Q1 2021",Coalition for Epidemic Preparedness Innovations (CEPI),1/5/2021
OncoGen,Protein subunit,Pre-clinical,Unknown,Unknown,Prior to 4/20/2020
Covaxx/ University of Nebraska Medical Center (UNMC)/ DASA/ United Biomedical Inc. Asia,Protein subunit,Phase I,"Phase I interim data announced 2/8/2021; Phase II began February 2021; Phase II clinical trials granted conditional approval by Taiwan's Ministry of Health and Welfare on 1/29/2021; Phase II/III expected to begin (US, Brazil, Taiwan, and India) in early 2021; Phase I began September 2020; Large scale human efficacy clinical trials expected to be conducted in Brazil and the US",Ministry of Health and Welfare in Taiwan,3/9/2021
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",Protein subunit,Pre-clinical,Unknown,Unknown,8/31/2020
"Applied Biotechnology Institute, Inc.",Protein subunit,Pre-clinical,Unknown,Unknown,5/12/2020
University of Alberta,Protein subunit,Pre-clinical,Unknown,Unknown,Prior to 4/20/2020
St. Petersburg Scientific Research Institute of Vaccines and Serums,Protein subunit,Pre-clinical,Unknown,Unknown,Prior to 4/20/2020
AdaptVac (PREVENT-nCoV consortium),Protein subunit,Pre-clinical,Pre-clinical data published January 2021; initial Phase I/IIa results expected to be released in Q1 2021,European Commission (Horizon 2020 Program),1/25/2021
Clover Biopharmaceuticals Inc./ Dynavax,Protein subunit,Phase I,"Clover and GSK discontinued their partnership as of February 2021; Phase I safety and immunogenicity data released December 2020 and published January 2021; Phase II/III trial with Dynavax adjuvant expected to begin during first half of 2021; Phase II/III trial with GSK adjuvant is not expected to move forward; Pre-clinical results released September 2020; CEPI partnership expanded in July and November 2020, Phase I trial began June 2020, preliminary results expected in the near future",Coalition for Epidemic Preparedness (CEPI),2/11/2021
Walter Reed Army Institute of Research (WRAIR) / U.S. Army Medical Research and Development Command,Protein subunit,Pre-clinical,Phase I expected to begin April 2021,Unknown,3/9/2021
Flow Pharma,Protein subunit,Pre-clinical,Unknown,Unknown,Prior to 4/20/2020
Neovii/Tel Aviv University,Protein subunit,Pre-clinical,Unknown,Unknown,5/19/2020
Sorrento Therapeutics,Protein subunit,Pre-clinical,Animal study results released July 2020,Unknown,8/17/2020
EpiVax / University of Georgia,Protein subunit,Pre-clinical,Unknown,Unknown,Prior to 4/20/2020
Generex / EpiVax,Protein subunit,Pre-clinical,Unknown,Unknown,Prior to 4/20/2020
Vaxil Bio,Protein subunit,Pre-clinical,Unknown,Unknown,Prior to 4/20/2020
BiOMVis Srl/ University of Trento,Protein subunit,Pre-clinical,Unknown,Unknown,5/12/2020
University of Pittsburgh,Protein subunit,Pre-clinical,Phase I to start as early as June 2020,Unknown,Prior to 4/20/2020
SK Biosciences/ GSK,Protein subunit,Pre-clinical,Phase I/II enrollment began February 2021,Gates Foundation/ Coalition for Epidemic Preparedness (CEPI),2/12/2021
"Osaka University / BIKEN / National Institutes of Biomedical Innovation, Japan",Protein subunit,Pre-clinical,Unknown,Unknown,Prior to 4/20/2020
Vabiotech,Protein subunit,Pre-clinical,Unknown,Unknown,11/16/2020
AnyGo Technology,Protein subunit,Pre-clinical,Unknown,Unknown,5/4/2020
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",Protein subunit,Phase I/II,Efficacy results expected to be announced in February 2021; Received early approval for use in Russia in October 2020; Phase I/II trial began end of July 2020,Unknown,1/19/2021
UMN Pharma (Shionogi),Protein subunit,Pre-clinical,Phase I to start by end of 2020,Japan Agency for Medical Research and Development,5/10/2020
"IMV, Inc., Canadian Center for Vaccinology at Dalhousie University, Izaak Walton Killam Health Center, Nova Scotia Health Authority, Canadian Immunization Research Network, University of Laval, Global Urgent and Advanced Research and Development in Canada",Protein subunit,Pre-clinical,Phase I/II expected to begin by end of 2020,"National Research Council of Canada Industrial Research Assistance Program (NRC IRAP), Atlantic Canada Opportunities Agency (ACOA), and Next Generation Manufacturing Canada (NGen)",11/16/2020
EpiVax ,Protein subunit,Pre-clinical,Unknown,Unknown,5/27/2020
Lomonosov Moscow State University,Protein subunit,Pre-clinical,Unknown,Unknown,5/27/2020
Kentucky BioProcessing (British American Tobacco),Protein subunit,Pre-clinical,"Phase I/II began recruiting December 2020, results expected mid-2021",Unknown,2/27/2021
"Chulalongkorn University/ GPO, Thailand",Protein subunit,Pre-clinical,Unknown,Unknown,6/1/2020
PDS Biotechnology,Protein subunit,Pre-clinical,Unknown,Unknown,6/2/2020
"Verndari/ University of California, Davis",Protein subunit,Pre-clinical,"Preliminary pre-clinical results are expected in the second half of 2020, Phase I trial is expected to begin thereafter; Selected by BARDA DRIVe for support in August 2020","Biomedical Advanced Research and Development Authority (BARDA) Division of Research, Innovation, and Ventures (DRIVe)",8/27/2020
Max-Planck Institute of Colloids and Interfaces,Protein subunit,Pre-clinical,Unknown,KHAN-1 Technology Transfer Fund I GmbH & Co KG,11/10/2020
"MOGAM Institute for Biomedical Research, GC Pharma",Protein subunit,Pre-clinical,Unknown,Unknown,11/16/2020
"University of San Martin and CONICET, Argentina",Protein subunit,Pre-clinical,Unknown,Unknown,6/12/2020
Intravacc/Epivax,Protein subunit,Pre-clinical,Unknown,Unknown,6/12/2020
Baiya Phytopharm/ Chula Vaccine Research Center,Protein subunit,Pre-clinical,Unknown,Unknown,6/18/2020
"Helix Biogen Consult, Ogbomoso & Trinity Immonoefficient Laboratory, Ogbomoso, Oyo State, Nigeria",Protein subunit,Pre-clinical,Unknown,Unknown,6/30/2020
"National
  Research Centre, Egypt",Protein subunit,Pre-clinical,Unknown,Unknown,6/30/2020
University of Virginia,Protein subunit,Pre-clinical,Unknown,Unknown,7/8/2020
Izmir Biomedicine and Genome Center,Protein subunit,Pre-clinical,Unknown,Unknown,7/9/2020
Bogazici University,Protein subunit,Pre-clinical,Unknown,Unknown,7/9/2020
InnoMedica,Protein subunit,Pre-clinical,Unknown,Unknown,7/9/2020
Mynvax,Protein subunit,Pre-clinical,Unknown,Unknown,7/15/2020
"Research
  Institute for Biological Safety Problems, Rep of Kazakhstan",Protein subunit,Pre-clinical,Unknown,Unknown,8/3/2020
Instituto Finlay de Vacunas,Protein subunit,Phase I/II,Phase I/II began August 2020,Unknown,3/9/2021
Soligenix/ University of Hawaii at Mānoa,Protein subunit,Pre-clinical,Pre-clinical testing results released in July 2020,"Soligenix, Inc. ",8/27/2020
Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana Cayetano Heredia (UPCH),Protein subunit,Pre-clinical,Unknown,Unknown,1/19/2021
"West China Hospital, Sichuan University",Protein subunit,Phase II,Phase II began November 2020; Phase I began end of August 2020; Animal study data published July 2020,Unknown,2/4/2021
"Adimmune
  Corporation",Protein subunit,Phase I,Phase I began end of August 2020; Phase II expected to begin November 2020,Unknown,9/2/2020
University Hospital Tuebingen,Protein subunit,Phase I,Phase I began December 2020,Unknown,2/27/2021
Instituto Finlay de Vacunas,Protein subunit,Phase III,Phase III began March 2021; Phase II began December 2020; Phase I began October 2020,Unknown,3/9/2021
Tampere University,Protein subunit,Pre-clinical,Unknown,Unknown,11/10/2020
Ohio State University/ Kazakh National Agrarian University,Protein subunit,Pre-clinical,Unknown,Unknown,11/10/2020
Kazakh National Agrarian University,Protein subunit,Pre-clinical,Unknown,Unknown,11/10/2020
Neo7Logix,Protein subunit,Pre-clinical,Unknown,Unknown,11/16/2020
"Kazakh National Agrarian University, Kazakhstan/ National Scientific Center for Especially Dangerous Infections",Protein subunit,Pre-clinical,Unknown,Unknown,11/10/2020
"Nanogen
  Pharmaceutical Biotechnology",Protein subunit,Phase I/II,Phase I/II began December 2020,Unknown,1/5/2021
University  Medical Center Groningen/ Akston Biosciences Corporation/ LakePharma,Protein subunit,Pre-clinical,Phase I/II expected to begin January 2021,Unknown,1/12/2021
"Center for Genetic Engineering and Biotechnology (CIGB), Havana",Protein subunit,Phase I/II,Phase I of Phase I/II (MAMBISA) trial began December 2020,Unknown,1/31/2021
"Center for Genetic Engineering and Biotechnology (CIGB), Havana",Protein subunit,Phase I,"Phase II expected to begin February 2021, Phase I (ABDALA) trial began December 2020",Unknown,1/31/2021
Razi Vaccine and Serum Research Institute,Protein subunit,Phase I,Phase I began end of February 2021,Unknown,3/4/2021
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",Replicating viral vector,Pre-clinical,Unknown,Unknown,8/31/2020
DZIF - German Center for Infection Research/ CanVirex AG,Replicating viral vector,Pre-clinical,Unknown,Unknown,6/30/2020
"The Lancaster University, UK",Replicating viral vector,Pre-clinical,Unknown,Unknown,5/19/2020
Zydus Cadila Healthcare Limited ,Replicating viral vector,Pre-clinical,Unknown,Unknown,7/8/2020
The University of Hong Kong/ Xiamen University/ Wantai Biological Pharmacy,Replicating viral vector,Phase II,Phase II reportedly began November 2020; Phase I reportedly began September 2020; ; Approved for clinical trials in September 2020,Coalition for Epidemic Preparedness (CEPI),1/31/2021
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",Replicating viral vector,Pre-clinical,Unknown,Unknown,8/31/2020
Shenzhen Geno-Immune Medical Institute,Replicating viral vector,Phase I,Phase I reportedly began February 2020,Unknown,1/31/2021
KU Leuven,Replicating viral vector,Pre-clinical,Unknown,Unknown,5/4/2020
BIOCAD / IEM,Replicating viral vector,Pre-clinical,Unknown,Unknown,Prior to 4/20/2020
Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ.,Replicating viral vector,Pre-clinical,Unknown,Unknown,5/19/2020
University of Wisconsin-Madison / FluGen/ Bharat Biotech,Replicating viral vector,Pre-clinical,Start Phase I trial in fall 2020,Unknown,5/4/2020
Tonix Pharma / Southern Research,Replicating viral vector,Pre-clinical,Preliminary preclinical results reported on 3/17/2021,Unknown,3/17/2021
University of Western Ontario,Replicating viral vector,Pre-clinical,Unknown,Unknown,Prior to 4/20/2020
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",Replicating viral vector,Pre-clinical,Unknown,Unknown,8/31/2020
Fundacao Oswaldo Cruz and Instituto Buntantan,Replicating viral vector,Pre-clinical,Unknown,Unknown,5/27/2020
"Israel
  Institute for Biological Research/ Weizmann Institute of Science",Replicating viral vector,Phase I/II,Phase I/II began November 2020,Unknown,1/31/2021
Aurobindo,Replicating viral vector,Pre-clinical,Unknown,Unknown,7/15/2020
Farmacológicos Veterinarios SAC (FARVET SAC),Replicating viral vector,Pre-clinical,Unknown,Unknown,1/19/2021
University of Manitoba,Replicating viral vector,Pre-clinical,Unknown,Unknown,11/9/2020
"Cellid
  Co., Ltd./IAVI",Replicating viral vector,Phase I/II,Phase I/IIa trial began December 2020,Unknown,1/31/2021
"Farmacológicos
  Veterinarios SAC (FARVET SAC)",Replicating viral vector,Pre-clinical,Unknown,Unknown,1/19/2021
"Aivita Biomedical, Inc./ National Institute of Health Research and Development, Ministry of Health Republic of Indonesia",Replicating viral vector,Phase I,Phase I/II expected to begin February 2021; Phase I began December 2020,Unknown,1/31/2021
Mahidol University/ The Government Pharmaceutical Organization (GPO)/ Icahn School of Medicine at Mount Sinai,Replicating viral vector,Pre-clinical,Phase I/II expected to begin March 2021,Unknown,2/27/2021
Fudan University / Shanghai JiaoTong University / RNACure Biopharma,RNA-based vaccine,Pre-clinical,Unknown,Unknown,Prior to 4/20/2020
"Greenlight Biosciences
",RNA-based vaccine,Pre-clinical,Unknown,Unknown,5/12/2020
Moderna/ National Institute of Allergy and Infectious Diseases (NIAID)/ Biomedical Advanced Research and Development Authority (BARDA)/ Lonza/ Catalent/ Rovi/ Medidata/ BIOQUAL/ Baxter BioPharma Solutions,RNA-based vaccine,Authorized,"First participants dosed in Phase II/III study (KidCOVE) in pediatric population less than 12 years of age on 3/16/2021; First participants dosed with modified COVID-19 vaccines, designed to address the potential need for booster vaccine candidates, in an amendment to the ongoing Phase II clinical study on 3/10/21; Provided strategy update for addressing SARS-CoV-2 variants of concern, including a variant-specific booster candidate (mRNA-1273.351) based on the B.1.351 variant first identified in the Republic of South Africa, on 2/24/2021; Results from an in vitro study on neutralization of variants of SARS-CoV-2 by mRNA-1273 vaccine-elicited sera announced January 2021; Phase I/II dosed in Japan (TAK-919) on 01/21/2021; Switzerland ""authorized"" on 01/12/2021; U.K. MHRA granted ""temporary authorization"" on 01/08/2021; European Commission granted a ""conditional marketing authorization"" on 01/06/2021; Israel granted ""authorization to import"" on 01/04/2021; Phase III interim safety and primary efficacy results published on 12/30/2020; Health Canada ""authorized"" on 12/23/2020; U.S. FDA issued ""emergency use authorization"" on 12/18/2020; Phase II/III study in adolescents ages 12 to less than 18 dosed on 12/10/2020; Submitted Emergency Use Authorization (EUA) request to the U.S. FDA on 11/30/2020; Phase III primary efficacy analysis results announced 11/30/2020; European Medicines Agency (EMA) started rolling review on 11/17/2020; Phase III interim analysis results announced 11/16/2020; Swissmedic started rolling review on 11/13/2020; UK Medicines and Healthcare products Regulatory Agency (MHRA) started rolling review on 10/27/2020; EMA confirmed marketing authorization submission eligibility on 10/14/2020; Health Canada rolling submission initiated on 10/13/2020; Study protocol for late-stage clinical trials released September 2020; Phase I interim data from older adult cohorts released Aug 2020 and published Sep 2020; Phase III COVE study began July 2020, completed enrollment on 10/22/2020; Animal study results published July/Aug 2020; Phase I interim results published July 2020; FDA fast track designation granted May 2020; Selected for US Operation Warp Speed in April 2020",Coalition for Epidemic Preparedness (CEPI)/ Biomedical Advanced Research and Development Authority (BARDA),3/16/2021
CanSino Biologics/Precision Nanosystems,RNA-based vaccine,Pre-clinical,Unknown,Unknown,5/21/2020
BIOCAD,RNA-based vaccine,Pre-clinical,Animal studies begin in April 2020,Unknown,Prior to 4/20/2020
GeneOne Life Science / Houston Methodist,RNA-based vaccine,Pre-clinical,Unknown,Unknown,1/5/2021
eTheRNA Immunotherapies / EpiVax/ Nexelis/ REPROCELL / Centre for the Evaluation of Vaccination of the University of Antwerp,RNA-based vaccine,Pre-clinical,Start Phase I early 2021,Unknown,5/4/2020
China CDC / Tongji University / Stermina,RNA-based vaccine,Pre-clinical,Unknown,Unknown,Prior to 4/20/2020
Daiichi-Sankyo/ University of Tokyo's Institute of Medical Science,RNA-based vaccine,Pre-clinical,Clinical studies expected to begin March 2021,Unknown,8/31/2020
"Arcturus/Duke-NUS/ Catalent
",RNA-based vaccine,Phase I/II,"Phase IIa of Phase I/II trial began recruiting January 2021; Received approval to proceed with Phase II study in Singapore (December 2020) and the US (January 2021); Phase I/II interim data released December 2020; Pre-clinical results released September and December 2020; Phase I/II began August 2020, initial results expected Q4 2020; Received approval to launch clinical trials in Singapore end of July 2020",Unknown,2/4/2021
"Centro Nacional Biotecnologia (CNB-CSIC), Spain",RNA-based vaccine,Pre-clinical,Unknown,Unknown,Prior to 4/20/2020
CureVac/Bayer/Novartis,RNA-based vaccine,Phase III,"Initiated rolling submission with European Medicines Agency (EMA) on 2/12/2021; Phase III trial began December 2020; Phase IIb/III (HERALD) trial began recruiting December 2020; Phase IIa trial began end of September 2020; Phase I trial began June 2020, interim results reported November 2020; Pre-clinical data released October 2020",Coalition for Epidemic Preparedness (CEPI); European Commission; Gates Foundation; Defense Advanced Research Projects Agency (DARPA); German Government; European Investment Bank (EIB); German Federal Ministry of Education and Research (BMBF),3/4/2021
Imperial College London/ VacEquity Global Health,RNA-based vaccine,Phase I/II,Pre-clinical results published July 2020; Phase I/II trial began June 2020,UK Government,9/10/2020
Fudan University / Shanghai JiaoTong University / RNACure Biopharma,RNA-based vaccine,Pre-clinical,Unknown,Unknown,Prior to 4/20/2020
Sanofi Pasteur/ Translate Bio,RNA-based vaccine,Pre-clinical,"Phase I expected to be dosed March 2021, interim results expected in 3Q 2021; Pre-clinical results released October 2020",Unknown,3/14/2021
"RNAimmune, Inc.",RNA-based vaccine,Pre-clinical,Unknown,Unknown,5/4/2020
BioNTech/ Pfizer/ Fosun Pharma/ Rentschler Biopharma,RNA-based vaccine,Authorized,"Evaluation of the safety and immunogenicity of a third dose (30 µg booster of the current vaccine) 6 to 12 months after receiving initial two-dose regimen began 2/25/2021; New stability data at standard freezer temperature was submitted to the U.S. FDA as of 2/19/2021; Results from in vitro studies on neutralization of variants of SARS-CoV-2 by BNT162b2 vaccine-elicited sera announced January 2021; Phase I (China) preliminary safety and immunogenicity data released January 2021; Argentina authorized under ""emergency registration"" on 12/22/2020; European Commission granted a ""conditional marketing authorisation"" (CMA) on 12/21/2020, following European Medicines Agency (EMA) recommendation to grant CMA; U.S. FDA issued ""emergency use authorization"" on 12/11/2020; Mexico COFEPRIS granted ""emergency use authorization"" on 12/11/2020; Saudi Food and Drug Authority (SFDA) ""approved the registration"" of the vaccine on 12/10/2020; Health Canada ""authorized"" on 12/9/2020; Bahrain granted ""emergency use authorization"" on 12/4/2020; U.K. MHRA granted ""temporary authorization for emergency use"" on 12/2/2020; Submitted Emergency Use Authorization (EUA) request to the U.S. FDA on 11/20/2020; Phase III complete analysis results announced 11/18/2020, interim analysis results announced 11/09/2020; Phase I data published October 2020; FDA approved late-stage trial enrollment of children 12 years and older in October 2020; EMA rolling submission initiated on 10/6/2020; Study protocol for late-stage clinical trials released Sept 2020; Amended protocol to FDA to expand trial enrollment to 44,000 participants; Phase IIb/III trial began Jul 2020; FDA granted Fast Track designation for BNT162b1 and BNT162b2 in Jul 2020; Selected for US Operation Warp Speed in Jul 2020; Phase I/II began Apr 2020; preliminary data released Jul 2020, additional data published Aug, Sept, and Dec 2020; Pre-clinical data released Sept 2020 and Dec 2020",Unknown,3/9/2021
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",RNA-based vaccine,Pre-clinical,Unknown,Unknown,8/31/2020
Ziphius Therapeutics/ Ghent University,RNA-based vaccine,Pre-clinical,Unknown,Unknown,4/28/2020
"IDIBAPS- Hospital Clinic, Spain",RNA-based vaccine,Pre-clinical,Unknown,Unknown,6/1/2020
Max-Planck Institute of Colloids and Interfaces,RNA-based vaccine,Pre-clinical,Unknown,KHAN-1 Technology Transfer Fund I GmbH & Co KG,11/9/2020
Chimeron Bio/ George Mason University's National Center for Biodefense and Infectious  Disease,RNA-based vaccine,Pre-clinical,Unknown,Unknown,6/17/2020
Chula Vaccine Research Center/University of Pennsylvania,RNA-based vaccine,Pre-clinical,Phase I expected to begin May 2021,Unknown,2/27/2021
People's Liberation Army (PLA) Academy of Military Sciences/ Walvax Biotech,RNA-based vaccine,Phase I,"Phase Ib began end of October 2020, Phase I trial began end of June 2020",Unknown,2/27/2021
Selcuk University,RNA-based vaccine,Pre-clinical,Unknown,Unknown,7/9/2020
Gennova,RNA-based vaccine,Pre-clinical,Unknown,Unknown,7/15/2020
Elixirgen Therapeutics/ Fujita Health University,RNA-based vaccine,Pre-clinical,"Clinical trials are expected to begin at Fujita Health University Hospital in Aichi, Japan in Q1 2021",Japan Agency for Medical Research and Development (AMED),9/1/2020
"Globe Biotech Limited, Bangladesh",RNA-based vaccine,Pre-clinical,Phase I/II protocol submitted to Bangladesh Medical Research Council (BMRC) on 1/17/2021 for approval to begin clinical trials,Unknown,1/18/2021
"Infectious Disease Research Institute/ Amyris, Inc.",RNA-based vaccine,Pre-clinical,Phase I expected to begin mid-2021,Unknown,11/16/2020
Curevac/GSK,RNA-based vaccine,Pre-clinical,"CureVac and GSK aim to develop a multi-valent candidate vaccine to address emerging variants for pandemic and endemic use; Development to begin immediately (February 2021) targeting vaccine availability in 2022, subject to regulatory approval",Unknown,2/5/2021
CureVac/UK Government (Vaccines Taskforce),RNA-based vaccine,Pre-clinical,Collaboration to develop and manufacture variant vaccines for commercial supply and distribution in the UK and its territories was entered in February 2021,Unknown,2/5/2021
Providence Therapeutics Holdings Inc.,RNA-based vaccine,Phase I,Phase I dosed January 2021,Unknown,2/27/2021
University of Manitoba,Virus-like particle,Pre-clinical,Unknown,Unknown,11/9/2020
Medicago Inc./ GlaxoSmithKline,Virus-like particle,Phase II/III,Phase III portion of the ongoing Phase II/III trial began March 2021;Phase II portion of the Phase II/III trial dosed December 2020; Phase II/III began recruiting November 2020; Phase I interim results released November 2020; Phase I began July 2020,Unknown,3/16/2021
"ARTES Biotechnology
",Virus-like particle,Pre-clinical,Unknown,Unknown,5/4/2020
University of Sao Paulo,Virus-like particle,Pre-clinical,Unknown,Unknown,5/19/2020
VBI Vaccines / National Research Council of Canada/ Therapure Biomanufacturing,Virus-like particle,Pre-clinical,"Phase I/II trial of VBI-2902a expected to begin March 2021; Phase I trial of VBI-2905, targeting the B.1.351 variant, expected to begin mid-year 2021",Coalition for Epidemic Preparedness (CEPI),3/14/2021
Saiba GmbH,Virus-like particle,Pre-clinical,Unknown,Unknown,Prior to 4/20/2020
Doherty Institute,Virus-like particle,Pre-clinical,Unknown,Unknown,7/8/2020
Imophoron Ltd / Bristol University's Max Planck Centre,Virus-like particle,Pre-clinical,Unknown,Unknown,Prior to 4/20/2020
OSIVAX,Virus-like particle,Pre-clinical,Unknown,European Innovation Council (EIC),7/9/2020
Mahidol University/ The Government Pharmaceutical Organization (GPO)/ Siriraj Hospital,Virus-like particle,Pre-clinical,Unknown,Unknown,6/30/2020
"Navarrabiomed, Oncoimmunology group",Virus-like particle,Pre-clinical,Unknown,Unknown,6/1/2020
IrsiCaixa AIDS Research/ IRTA-CReSA/ Barcelona Supercomputing Centre/ Grifols,Virus-like particle,Pre-clinical,Unknown,Unknown,6/23/2020
Middle East Technical University,Virus-like particle,Pre-clinical,Unknown,Unknown,7/9/2020
Medicago Inc./ Dynavax,Virus-like particle,Pre-clinical,Phase I to start mid-July 2020,Unknown,7/10/2020
"Medicago
  Inc./ GSK",Virus-like particle,Pre-clinical,Unknown,Unknown,7/14/2020
Bezmialem Vakif University,Virus-like particle,Pre-clinical,Unknown,Unknown,7/21/2020
Serum Institute of India/ Accelagen Pty/ SpyBiotech,Virus-like particle,Phase I/II,Phase I of follow up Phase I/II clinical trial adjuvanted with CpG 1018 dosed December 2020; Phase I/II began September 2020,Unknown,1/31/2021
Tampere University,Virus-like particle,Pre-clinical,Unknown,Unknown,11/9/2020
Max-Planck Institute for Dynamics of Complex Technical Systems,Virus-like particle,Pre-clinical,Unknown,Unknown,11/9/2020
Icosavax,Virus-like particle,Pre-clinical,Phase I expected to begin mid-2021; Pre-clinical results published October 2020,Unknown,11/18/2020
Arizona State University ,Virus-like particle,Pre-clinical,Unknown,Unknown,2/12/2021
Arizona State University ,Virus-like particle,Pre-clinical,Unknown,Unknown,2/12/2021
"Catholic University/ Millennium Institute of Immunology and Immunotherapy/ Technological Consortium in Clinical Molecular Biomedicine, Chile",Unknown,Pre-clinical,Unknown,Unknown,4/23/2020
Tulane University,Unknown,Pre-clinical,Unknown,Unknown,Prior to 4/20/2020
ISR Immune System Regulation,Unknown,Pre-clinical,"Animal study results expected in Q2 2020, Phase I begins Q4 2020",Unknown,Prior to 4/20/2020
HaloVax (Voltron Therapeutics) / The Vaccine & Immunotherapy Center at the Massachusetts General Hospital,Unknown,Pre-clinical,Animal study results by October 2020,Analog Devices Foundation,4/21/2020
Vir Biotechnology / GSK,Unknown,Pre-clinical,Unknown,Unknown,Prior to 4/20/2020
Emergex Vaccines/ George Mason University's National Center for Biodefense and Infectious Diseases (NCBID),Unknown,Pre-clinical,Unknown,Unknown,4/24/2020
AbVision,Unknown,Pre-clinical,Unknown,Unknown,5/13/2020
Precision Vaccines Program at Boston Children's Hospital,Unknown,Pre-clinical,Unknown,Unknown,Prior to 4/20/2020
"Oragenics (Noachis Terra)/ Aragen Bioscience
",Unknown,Pre-clinical,Phase I expected to start in early 2021,Unknown,9/28/2020
Vivaldi Biosciences/ Esco Aster Pte Ltd,Unknown,Pre-clinical,Unknown,Unknown,6/2/2020
Adeleke University,Unknown,Pre-clinical,Unknown,Unknown,6/30/2020
Codiak BioSciences/ Ragon Institute,Unknown,Pre-clinical,Unknown,Unknown,6/4/2020
Vault Pharma/ University of California Los Angeles,Unknown,Pre-clinical,Unknown,Unknown,6/17/2020
NidoVax,Unknown,Pre-clinical,Unknown,Unknown,6/18/2020
"United
  Biomedical (UBI)/ c19",Unknown,Pre-clinical,,Unknown,9/2/2020
"OSE
  Immunotherapeutics",Unknown,Pre-clinical,"Clinical
  trials expected to begin end of 2020/early 2021; Pre-clinical results
  released in August 2020",Unknown,11/9/2020
"University of California, Los Angeles (Horwitz Lab)",Replicating bacterial vector,Pre-clinical,Unknown,Unknown,5/10/2020
Farmacológicos Veterinarios SAC (FARVET SAC),Replicating bacterial vector,Pre-clinical,Unknown,Unknown,1/19/2021
Institut Pasteur/ Themis/ University of Pittsburgh CVR/ Merck Sharp & Dohme,Dormant / Discontinued,Phase I/II,Development discontinued following review of Phase I findings on 1/25/2021; Phase I results to be submitted for publication; Phase I/II began September 2020; Animal testing began April 2020,Coalition for Epidemic Preparedness (CEPI),1/25/2021
IAVI/ Merck,Dormant / Discontinued,Pre-clinical,Development discontinued following review of Phase I findings on 1/25/2021; Phase I results to be submitted for publication; Phase I enrollment began November 2020; Selected for US Operation Warp Speed in April 2020; clinical studies to start in 2020,Biomedical Advanced Research and Development Authority (BARDA); Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DoD),1/25/2021
Wuhan Jinyintan Hospital,Dormant / Discontinued,Clinical,No trial updates since February 2020,Unknown,7/27/2020
Sanofi / Regeneron; Feinstein Institutes; REMAP-CAP global trial,Dormant / Discontinued,Clinical,"Phase III (US) results released July 2020 and US trial stopped, Phase III (ex-US in severe and critical hospitalized patients continues) results expected 3Q 2020; trials outside of US stopped",Biomedical Advanced Research and Development Authority (BARDA),9/2/2020
"Hu'nan Haiyao hongxingtang Pharmaceutical Co., Ltd (Novaferon) 
",Dormant / Discontinued,Clinical,Unknown,Unknown,7/27/2020
The First Affiliated Hospital of Fujian Medical University/Novartis,Dormant / Discontinued,Clinical,,Unknown,7/27/2020
University of Queensland/CSL/Seqirus,Dormant / Discontinued,Phase I,Phase I results released February 2021; Phase II/III trials will not proceed following Phase I completion (announced 12/11/2020); Phase I trial began July 2020,Coalition for Epidemic Preparedness (CEPI)/Queensland Government/Federal Government (Australia)/Paul Ramsay Foundation,2/16/2021
The First Affiliated Hospital of Guangzhou Medical University,Dormant / Discontinued,Clinical,,,Prior to 4/20/2020
The Second Hospital of Nanjing Medical University,Dormant / Discontinued,Clinical,,,Prior to 4/20/2020
"Mianyang Central Hospital 
",Dormant / Discontinued,Clinical,"Chinese trial site last updated March 30, 2020",,5/7/2020
Numerous trials with Chinese research sponsors,Dormant / Discontinued,Clinical,"Chinese trial site last updated February 16, 2020 - March 4, 2020 for various trials",,5/7/2020
"Roche/the First Hospital Affiliated to Zhejiang University's Medical School
",Dormant / Discontinued,Clinical,"Chinese trial site last updated February 12, 2020",,5/10/2020